Navigation Links
BiOptix continues support of Colorado-based research institutions
Date:6/15/2012

BOULDER, Colo., June 15, 2012 /PRNewswire/ -- BiOptix, a Colorado-based firm, announces completion of a successful week of research shows in Colorado's Biotech Corridor.

BiOptix today announced support of events this week at National Jewish Health, the University of Colorado Denver-Anschutz Medical Campus and at the University of Colorado, Boulder.  These events brought Colorado-based researchers together with representatives of dozens of global life science research suppliers, and are a critical link in the research supply and innovation chain.  The strength and participation at these events highlight the significant research activities that exist in Colorado, and BiOptix, as a Boulder, Colorado-based company is proud to support the continued development and expansion of these efforts. 

Supporting Colorado's Growing Biotech Corridor—and our hometown of Boulder.     

Colorado's growing biotech corridor is concentrated in the Denver-Boulder metropolitan areas allowing BiOptix strategic access to these markets.  "After completing a successful show at the University of California San Francisco, last week, we are excited to turn our attention toward our home market of Colorado for this series of events," noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix.  "We are grateful to have the support of our colleagues in Denver and especially in our hometown of Boulder. Colorado represents a significant opportunity to us as a supplier, not to mention what Colorado means to the global research community—it is awesome to be here."

BiOptix Events

So far in 2012, BiOptix has participated in 8 nation-wide life science industry events and has showcased a novel and patented ultra-sensitive biosensor platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional Surface Plasmon Resonance, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.  BiOptix anticipates more than 30 customer facing events in 2012, with additional planned in 2013.

About BiOptix

BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance.  BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com


'/>"/>
SOURCE BiOptix Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Profil Institute Continues to Publish New Findings in Metabolic Research
2. AMPAC Fine Chemicals Continues to Invest in Quality Systems
3. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
4. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
5. Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
6. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
7. Fluke Biomedical training center goes global: adds multi-language support
8. MDA Supports Development of Dissociative Glucocorticoid for DMD
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
11. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017   Pulmatrix, Inc . (NASDAQ: ... developing innovative inhaled therapies to address serious pulmonary diseases, ... infections in the lungs of CF patients, PUR1900, has ... by the U.S. Food & Drug Administration. ... to speed the development of novel drugs against important ...
(Date:1/17/2017)...  Only nine percent of U.S. consumers believe pharmaceutical ... 16 percent believe health insurance companies do, according to ... of U.S. adults believe health care providers (such as ... hospitals (23%). "We are in the midst ... , vice president of reputation management and public affairs ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Pono ... balanced, peaceful and healthy lifestyle, announced today the official launch of its much-anticipated Pono ... the mind. , In development for over a year, the patented Pono ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, ... recently announced a collaboration with the Heidelberg University Hospital and the German Cancer ... preparation, following the company’s successful launch of its CATS (Capture and Amplification ...
Breaking Biology Technology:
(Date:12/16/2016)... -- Research and Markets has announced the addition of ... 2021" report to their offering. ... The biometric vehicle access system market, in ... 14.06% from 2016 to 2021. The market is estimated to be ... Million by 2021. The growth of the biometric vehicle access system ...
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
Breaking Biology News(10 mins):